Photodynamic activities and biodistribution of fluorinated zinc phthalocyanine derivatives in the murine EMT-6 tumour model.
The photodynamic properties and biodistribution pattern of zinc dodecafluoro-4-sulphophthalocyanine (ZnPcF12S1), zinc hexadecafluorophthalocyanine (ZnPcF16) and zinc phthalocyanine (ZnPc) were evaluated in the murine EMT-6 tumour model. All 3 dyes were formulated as a Cremophor oil-water emulsion after initial solubilization in methanol, acetone and pyridine, respectively. Comparison of their phototoxicity after in vitro incubation with EMT-6 cells and exposure to various fluences of red light showed that ZnPcF12S1 is about 50 times more active than ZnPcF16, reflecting better cell-penetrating properties. Solubilisation of ZnPc in 1-methyl-2-pyrrolidinone prior to formulation resulted in loss of photoactivity upon dilution in serum due to precipitation of the dye in the aqueous environment. In contrast, initial solubilisation in pyridine likely forms a ZnPc-pyridinium salt, and this preparation was 6 times more phototoxic than ZnPcF12S1. In vivo comparison of monosulphonated ZnPcF12S1 with perfluorinated ZnPcF16 showed improved pharmacokinetics in mice, including lower liver and spleen retentions and higher tumour-to-non-target tissue ratios. However, photodynamic therapy (PDT) of the EMT-6 tumour in BALB/c mice with red light, 24 or 48 hr post-injection of 1 micromol x kg(-1) of ZnPcF12S1 induced mortality. Lowering the drug and/or light dose or extending the time interval between drug administration and irradiation to 72 hr avoided adverse effects but also resulted in poor tumour response. The best tumour control (25% of animals) was obtained at 0.1 micromol x kg(-1) and a fluence of 400 J x cm(-2) at 24 hr post-injection. In contrast, ZnPcF16 required a 20-fold higher drug dose to induce a similar tumour response. The systemic shock following PDT with the amphiphilic ZnPcF12S1 likely results from extensive cellular effects.
Allémann
E
E
School of Pharmacy, University of Geneva, Switzerland.
Brasseur
N
N
Kudrevich
S V
SV
La Madeleine
C
C
van Lier
J E
JE
D000818:Animals; D005260:Female; D005456:Fluorescent Dyes / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007211:Indoles / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D054833:Isoindoles; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000628:therapy*; D051379:Mice; D009942:Organometallic Compounds / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010789:Phototherapy; D011838:Radiation-Sensitizing Agents / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015032:Zinc; D017967:Zinc Compounds
D005456:Fluorescent Dyes; D007211:Indoles; D054833:Isoindoles; D009942:Organometallic Compounds; D011838:Radiation-Sensitizing Agents; D017967:Zinc Compounds; C052159:Zn(II)-phthalocyanine; D015032:Zinc